| 1 |
Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect
Erik P. Pioro, Benjamin Rix Brooks, Jeffrey L. Cummings et al. · Annals of Neurology
|
13 Sep 2010 |
372 |
| 2 |
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus, Tiffany L. Baumann, Joao O. Siffert et al. · Neurology
Open access |
11 Apr 2013 |
215 |
| 3 |
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia
Jeffrey L. Cummings, Constantine G. Lyketsos, Elaine R. Peskind et al. · JAMA
|
22 Sep 2015 |
208 |
| 4 |
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Charles P. Taylor, Stephen F. Traynelis, Joao O. Siffert et al. · Pharmacology & Therapeutics
Open access |
May 2016 |
188 |
| 5 |
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis
HILLEL S. PANITCH, Ronald A. Thisted, Richard Alan Smith et al. · Annals of Neurology
|
21 Apr 2006 |
176 |
| 6 |
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY
Raj K. Maturi, Ayala Pollack, Harvey Siy Uy et al. · Retina
Open access |
12 Feb 2016 |
130 |
| 7 |
Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers
Laura E. Pope, M.H. Khalil, James E. Berg et al. · The Journal of Clinical Pharmacology
|
Sep 2004 |
125 |
| 8 |
The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions
Christopher K. Cote, Cynthia A. Rossi, Angray S. Kang et al. · Microbial Pathogenesis
|
24 Apr 2005 |
124 |
| 9 |
Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.
David H. Katz, John F. Marcelletti, Mina Khalil et al. · Proceedings of the National Academy of Sciences
Open access |
Dec 1991 |
108 |
| 10 |
Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology
Jesse Mez et al. · Alzheimer s & Dementia
Open access |
7 Apr 2021 |
107 |
| 11 |
Pseudobulbar affect: an under-recognized and under-treated neurological disorder
Susan S. Work, Jennifer Colamonico, Walter G. Bradley et al. · Advances in Therapy
Open access |
6 Jun 2011 |
105 |
| 12 |
Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients
Richard Alan Smith, James E. Berg, Laura E. Pope et al. · Multiple Sclerosis Journal
|
13 Nov 2004 |
101 |
| 13 |
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed
Ritsuko Sawada-Hirai, Ivy Jiang, Fei Wang et al. · Journal of Immune Based Therapies and Vaccines
Open access |
12 May 2004 |
98 |
| 14 |
The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process
Laura E. Pope, John F. Marcelletti, Lee R. Katz et al. · Antiviral Research
|
Dec 1998 |
95 |
| 15 |
Human Monoclonal Anti-Protective Antigen Antibody Completely Protects Rabbits and Is Synergistic with Ciprofloxacin in Protecting Mice and Guinea Pigs against Inhalation Anthrax
Johnny Wayne Peterson, Jason E. Comer, David M. Noffsinger et al. · Infection and Immunity
Open access |
21 Jan 2006 |
81 |
| 16 |
The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first‐in‐class antiepileptic drug that targets KCNQ (Kv7) potassium channels
Neil Brickel, Paul Gandhi, Kevan VanLandingham et al. · Epilepsia
|
16 Mar 2012 |
75 |
| 17 |
PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions
Benjamin Rix Brooks, David W. Crumpacker, Jonathan L. Fellus et al. · PLoS ONE
Open access |
21 Aug 2013 |
74 |
| 18 |
Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study
for the Ozurdex MEAD Study Group, Albert J. Augustin, Baruch D. Kuppermann et al. · BMC Ophthalmology
Open access |
30 Oct 2015 |
72 |
| 19 |
Pseudobulbar Affect: Burden of Illness in the USA
Jennifer Colamonico, Andrea E. Formella, Walter G. Bradley · Advances in Therapy
Open access |
30 Aug 2012 |
69 |
| 20 |
Human Monoclonal Antibody AVP-21D9 to Protective Antigen Reduces Dissemination of the Bacillus anthracis Ames Strain from the Lungs in a Rabbit Model
Johnny Wayne Peterson, Jason E. Comer, Wallace B. Baze et al. · Infection and Immunity
Open access |
24 Apr 2007 |
58 |
| 21 |
AVP ‐825 Breath‐Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
Stewart J. Tepper, Roger K. Cady, Stephen David Silberstein et al. · Headache The Journal of Head and Face Pain
Open access |
May 2015 |
56 |
| 22 |
Novel 2-(Substituted phenyl)benzimidazole Derivatives with Potent Activity against IgE, Cytokines, and CD23 for the Treatment of Allergy and Asthma
Mark L. Richards, Shirley Cruz Lio, Anjana Sinha et al. · Journal of Medicinal Chemistry
|
13 Nov 2004 |
51 |
| 23 |
Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study
Aziz I. Shaibani, Laura E. Pope, Ronald A. Thisted et al. · Pain Medicine
Open access |
Feb 2012 |
50 |
| 24 |
Thermodynamics of Fatty Acid Binding to Engineered Mutants of the Adipocyte and Intestinal Fatty Acid-binding Proteins
Gary V. Richieri, Pamela J. Low, Ronald T. Ogata et al. · Journal of Biological Chemistry
Open access |
Mar 1998 |
49 |
| 25 |
Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug
Laura E. Pope, John F. Marcelletti, Lee R. Katz et al. · Journal of Lipid Research
Open access |
Oct 1996 |
40 |
| 26 |
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
Flora McConnell Hammond, David N. Alexander, Andrew J. Cutler et al. · BMC Neurology
Open access |
4 Jun 2016 |
37 |
| 27 |
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
Gary L. Pattee, James P. Wymer, Catherine Lomen‐Hoerth et al. · Current Medical Research and Opinion
Open access |
25 Jul 2014 |
37 |
| 28 |
Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease
Susan Helen Fox, Leonard Verhagen Metman, John G. Nutt et al. · Movement Disorders
|
30 Mar 2017 |
35 |
| 29 |
2-Phenylimidazopyridines, a New Series of Golgi Compounds with Potent Antiviral Activity
Homayon Banie, Anjana Sinha, Richard J. Thomas et al. · Journal of Medicinal Chemistry
|
31 Oct 2007 |
34 |
| 30 |
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
Malcolm S. Mitchell, June Kan‐Mitchell, Philip R. Morrow et al. · Clinical Cancer Research
|
2004 |
33 |
| 31 |
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: A 29-day, multicenter, open-Label, dose-escalation study
Ronald A. Thisted, Leslie J. Klaff, Sherwyn Leon Schwartz et al. · Clinical Therapeutics
|
Oct 2006 |
33 |
| 32 |
Substituted 2-phenyl-benzimidazole derivatives: novel compounds that suppress key markers of allergy
Mark L. Richards, Shirley Cruz Lio, Anjana Sinha et al. · European Journal of Medicinal Chemistry
|
5 May 2006 |
32 |
| 33 |
Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs
John F. Marcelletti · Antiviral Research
|
7 Oct 2002 |
32 |
| 34 |
Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly
Fei Wang, Paul E. Ruther, Ivy Jiang et al. · Human Antibodies
|
22 Jan 2005 |
31 |
| 35 |
n‐Docosanol: Broad Spectrum Anti‐Viral Activity against Lipid‐enveloped Virusesa
David H. Katz, JOHN R. MARCELLETTI, Laura E. Pope et al. · Annals of the New York Academy of Sciences
|
May 1994 |
28 |
| 36 |
Topical application of docosanol‐ or stearic acid‐containing creams reduces severity of phenol burn wounds in mice
Mohammed Khalil, John F. Marcelletti, Lee R. Katz et al. · Contact Dermatitis
|
Aug 2000 |
27 |
| 37 |
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP‐825 Breath Powered ® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan
Stephen David Silberstein, Paul K Winner, Peter J. McAllister et al. · Headache The Journal of Head and Face Pain
|
11 May 2017 |
26 |
| 38 |
Measuring pseudobulbar affect in ALS
Richard Alan Smith, James E. Berg, Laura E. Pope et al. · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
|
Sep 2004 |
26 |
| 39 |
Results From a 2-Year Centralized Tolcapone Liver Enzyme Monitoring Program
Mark Lew, Greg Kricorian · Clinical Neuropharmacology
|
Sep 2007 |
24 |
| 40 |
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor.
Jonathan A. Chappel, William O. Rogers, Stephen L. Hoffman et al. · Malaria Journal
Open access |
2004 |
23 |
| 41 |
Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers
Kerri A. Schoedel, Laura E. Pope, Edward M. Sellers · Clinical Drug Investigation
|
31 Jan 2012 |
23 |
| 42 |
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM‐II Open Label Study
Flora McConnell Hammond, William M. Sauvé, Fred Ledon et al. · PM&R
Open access |
23 Feb 2018 |
22 |
| 43 |
Faster Improvement in Migraine Pain Intensity and Migraine‐Related Disability at Early Time Points with AVP‐825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study
Richard B. Lipton, James S. McGinley, Kenneth J. Shulman et al. · Headache The Journal of Head and Face Pain
|
7 Sep 2017 |
19 |
| 44 |
The Antiviral Drug Docosanol as a Treatment for Kaposi's Sarcoma Lesions in HIV Type 1-Infected Patients: A Pilot Clinical Study
Michael J. Scolaro, Lucy B. Gunnill, Laura E. Pope et al. · AIDS Research and Human Retroviruses
|
2001 |
19 |
| 45 |
Oxymetazoline and Energy‐Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open‐Label, Interventional Study
Emil A Tanghetti, David J. Goldberg, Jeffrey S. Dover et al. · Lasers in Surgery and Medicine
Open access |
6 May 2020 |
18 |
| 46 |
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE
Maria‐Eugenia Soto, Susan R. Abushakra, Jeffrey L. Cummings et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
2015 |
17 |
| 47 |
PRISM: A Novel Tool to Prospectively Estimate the Prevalence of Pseudobulbar Affect Symptoms
David W. Crumpacker, Jonathan L. Fellus, Daniel Kantor et al. · American Journal of Geriatric Psychiatry
Open access |
Mar 2013 |
17 |
| 48 |
IL-10 inhibits lipopolysaccharide-induced murine B cell proliferation and cross-linking of surface antigen receptors or ligation of CD40 restores the response
John F. Marcelletti · The Journal of Immunology
|
Oct 1996 |
16 |
| 49 |
AVP‐825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial
Richard B. Lipton, James S. McGinley, Kenneth J. Shulman et al. · Headache The Journal of Head and Face Pain
|
16 Oct 2017 |
15 |
| 50 |
Effects of stress on functional connectivity during verbal processing
Neetu Nair, John P. Hegarty, Bradley J. Ferguson et al. · Brain Imaging and Behavior
|
12 Dec 2019 |
14 |